Loading data for FTH — first visit, this takes a few seconds.
Faeth Therapeutics Inc. (FTH)
NasdaqCM: FTH
· Real-Time Price · USD
32.10
-1.01 (-3.05%)
At close: Aug 20, 2026, 8:00 PM
32.10
+0.00%
After-hours: 4:10 PM
Faeth Therapeutics Inc. (FTH) Stock Price, Analysis & Data
-3.05% (1D)
No data available
| Bid | 31.8 |
| Market Cap | 829.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -195.53M |
| Beta | -0.31 |
| EPS (ttm) | -60.86 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.47 |
| P/B (ttm) | 4.79 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 35 |
| Volume | 296,939 |
| Avg. Volume (20D) | 195,129 |
| Open | 33.42 |
| Previous Close | 33.11 |
| Day's Range | 30.75 - 33.42 |
| 52-Week Range | 7.45 - 37.90 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FTH
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 29
Stock Exchange NasdaqCM
Ticker Symbol FTH
Financial Performance
In 2025, Faeth Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -21.09M, a decrease of -30.08%.
Financial StatementsEarnings Surprise
Faeth Therapeutics has released their quarterly earnings on Aug 4, 2026:
Faeth Therapeutics Inc. is scheduled to release its earnings on Nov 3, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
